# PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy

> **NCT07463248** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Wang Xin** · enrollment: 64 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Tislelizumab Combined With TKI
- **DRUG:** Fecal Microbiota Transplantation
- **RADIATION:** PULSAR

## Key facts

- **NCT ID:** NCT07463248
- **Lead sponsor:** Wang Xin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-05
- **Primary completion:** 2028-01-31
- **Final completion:** 2029-01-31
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07463248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07463248, "PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07463248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*